PIKA Rabies Vaccine

Vaccine

Phase 3topline reported

Evidence outlook · registrational

Rabies Prevention and Post-Exposure Prophylaxis: topline reported 2024-04-09

Its supporting mid-stage studies have completed. The sponsor reported topline results on 2024-04-09 (Pivotal Phase 3 interim analysis meets primary endpoints). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Rabies Prevention and Post-Exposure Prophylaxis
Phase 2 (1)
Rabies Prevention and Post-Exposure Prophylaxis
NCT02956421 · Yisheng Biopharma (Singapore) Pte. Ltd.
2016-02 – 2016-10 · Rabies
What this study did
Phase 1 (1)
Rabies Prevention and Post-Exposure Prophylaxis
NCT02657161 · Yisheng Biopharma (Singapore) Pte. Ltd.
2015-02 – 2015-07 · Rabies
What this study did

Competitive landscape

This drug's own stage for Rabies Prevention and Post-Exposure Prophylaxis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PIKA Rabies Vaccine: this drugPhase 3VaccineRabies virus antigens (poly I:C-based adjuvant)not yet gradedNo reviewed efficacy summary in this indication
SP0087
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 November 2024Filing submittedBLA submission to Pakistan's DRAP initiated
PK, DRAP · LakeShore Biopharma · Source ↗
9 April 2024Topline resultPivotal Phase 3 interim analysis meets primary endpoints
YS Biopharma (now LakeShore Biopharma) · Source ↗